comparemela.com
  1. Home
  2. Live Updates
  3. Axel Dignass - Breaking News

Axel Dignass News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1. Results showed a.

United statesSpring houseBritish columbiaAxel dignassJan wehkampBridget kimmelGoethe university in frankfurtNone of the janssen pharmaceutical companiesJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonHead of the department medicineExchange commissionEuropean unionCompanies of johnsonColitis organisation

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

SPRING HOUSE, Pa., Feb. 18, 2022 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase .

United statesSpring houseBritish columbiaAxel dignassJan wehkampBridget kimmelGoethe university in frankfurtNone of the janssen pharmaceutical companiesCrohn colitis foundationDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonHead of the department medicineExchange commissionEuropean union

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1. Results showed a.

United statesSpring houseBritish columbiaAxel dignassJan wehkampBridget kimmelGoethe university in frankfurtNone of the janssen pharmaceutical companiesJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonHead of the department medicineExchange commissionEuropean unionCompanies of johnsonColitis organisation

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.